PRQR ProQR Therapeutics N.V. Company Net Income

Corporate emblem and logo of ProQR Therapeutics (PRQR)

The ProQR Therapeutics N.V. (PRQR) price chart demonstrates profit dynamics, which currently stand at -0.05. The business relies on the creation of advanced genetic drugs and diagnostics. Agile management prioritizes the most promising developments in the field of RNA. The stability of the Dutch startup is ensured by the absence of trade conflicts and global scientific partnerships in the medical sector.

PRQR ProQR Therapeutics NV: Company Net Income in the range 07/04/2022 - 10/30/2026

Comprehensive metric breakdowns and analytics for proqr.com (PRQR)

- stock price and consensus target price:
Price Performance Chart ProQR Therapeutics|PRQR - Price Target Chart
- market capitalization data:
Market Value PRQR|PRQR - Total Company Value
- balance sheet equity data:
Book Value of One Share ProQR Therapeutics N.V.|PRQR - Company Book Value|Market Value to Book Value proqr.com|PRQR - Cumulative Company Assets
- debt and liquidity details:
All Debt to Shareholders' Equity Ratio ProQR Therapeutics N.V.|PRQR - Long-Term Debt to Equity Ratio|Short-Term Loans to Capital Ratio ProQR Therapeutics|PRQR - Company Aggregate Debts|Debt to Net Assets Ratio PRQR|PRQR - Company Long-Term Debts|Short-Term Debt ProQR Therapeutics N.V.|Intermediate Coverage Ratio proqr.com
- business earnings and investment ratios data:
PRQR - Net Profit
Fundamental valuation:ProQR Therapeutics NV (PRQR)
Manufactured products of ProQR Therapeutics N.V.

ProQR Therapeutics N.V. (PRQR) is investing significant resources into a high-paid staff of RNA medicine experts. This indicator reflects the final financial result, recalculated on a daily scale to identify hidden cash gaps. The analysis allows for an assessment of the business model's resilience to operational disruptions amid intensive research funding. It is critical for investors to track volatility through the company's net bottom line, as this eliminates emotional noise when assessing fundamental risks.

Direct competitors

Tempus AI - Final Profit|Company Net Income Qiagen N.V.|Company Net Income ionispharma.com IONS|Company Net Income Repligen (RGEN)|Avidity Biosciences Inc (RNA) - Annual Net Income|Company Net Income CRISPR Therapeutics Corp CRSP|Final Profit WGS|RARE: Net Income|Final Profit BEAM (beamtx.com)|SRPT (Sarepta) - Net Income|TWST: Profit After Payment of Taxes|TXG (10x Genomics Corp) - Net Profit|NTLA: Final Profit|Net Profit STOK|BLFS - Company Net Income|Company Net Income Wave Life Sciences Ltd. WVE|Final Profit MAZE|Sionna Pharma - Net Profit|PRME - Net Profit|Taysha Gene Therapies (TSHA) - Company Net Income|Profit After Tax QURE (uniqure.com)|MGTX (MeiraGTx) - Net Profit|Company Net Income REGENXBIO Inc RGNX|Net Income SLDB (Solid Bio)|Net Profit Ocugen Pharma (OCGN)|Pacific Biosciences - Net Income|Profit After Payment of Taxes BNTC (benitec.com)|Design Therapeutics, Inc. - Net Profit|Net Financial Result Rocket Pharma RCKT|FDMT: Net Profit|Net Income Lexeo Therapeutics, Inc.|Company Net Income Korro Bio Inc.|editasmedicine.com (EDIT) - Net Financial Result|Net Income SLN (Silence Therapeutics plc)|CDXS (codexis.com) - Final Profit|Company Net Income Sangamo SGMO|NAUT: Company Profit|MGX: Net Income|Net Financial Result Precision BioSciences Inc. DTIL|GBIO (generationbio.com) - Net Income|BOLD (Boundless Bio Inc.) - Company Net Income|Net Income XCUR|Celsion Corporation (IMNN) - Net Financial Result|Company Net Income Phio Pharmaceuticals (PHIO)|MBIO: Profit After Tax|Company Net Income TransCode Therapeutics, Inc. RNAZ|Final Profit BNGO|APDN - Company Net Income|Annual Net Income bluebird bio, Inc (BLUE)|immunoprecise.com (IPA) - Company Net Income|omegatherapeutics.com - Final Profit|OMIC (Singular Genomics) - Net Profit|Company Profit RGLS (Regulus Therapeutics, Inc.)|Company Net Income Syros (SYRS)|Telesis Bio, Inc - Company Profit|Net Profit TCON (TRACON Pharmaceuticals)|Net Profit unitybiotechnology.com UBX